We are live on ! Find out more
LUMO

Lumos Pharma, Inc. Common Stock
LUMO

Delisted

LUMO was delisted on the 11th of December, 2024.

Back to rankings

40 hedge funds and large institutions have $32.1M invested in Lumos Pharma, Inc. Common Stock in 2021 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 5 increasing their positions, 12 reducing their positions, and 6 closing their positions.

New
Increased
Maintained
Reduced
Closed

2% less funds holding

Funds holding: 41 → 40 (-1)

17% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 6

17% less capital invested

Capital invested by funds: $38.8M → $32.1M (-$6.73M)

58% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 12

Holders
40
Holders Change
-1
Holders Change %
-2.44%
% of All Funds
0.7%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
5
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$1.78M
2
PAPAIJV
Paragon Associates & Paragon Associates II Joint Venture
Texas
+$557K
3
Wells Fargo
Wells Fargo
California
+$555K
4
State Street
State Street
Massachusetts
+$125K
5
MAM
Marquette Asset Management
Minnesota
+$99.3K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$3.78M
2
Renaissance Technologies
Renaissance Technologies
New York
-$297K
3
Two Sigma Investments
Two Sigma Investments
New York
-$123K
4
BlackRock
BlackRock
New York
-$105K
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
-$41.1K
Name Holding Trade Value Shares
Change 		Change in
Stake
WFA
26
West Financial Advisors
Iowa
$8K – – –
CAPTRUST Financial Advisors
27
CAPTRUST Financial Advisors
North Carolina
$4K +$4.45K +400 New
Royal Bank of Canada
28
Royal Bank of Canada
Ontario, Canada
$3K – – –
UBS Group
29
UBS Group
Switzerland
$1K -$13.6K -1,226 -92%
TRCT
30
Tower Research Capital (TRC)
New York
$1K -$1.28K -115 -48%
CFGS
31
Concourse Financial Group Securities
Alabama
$1K – – –
EVM
32
Eaton Vance Management
Massachusetts
$1K – – –
Fifth Third Bancorp
33
Fifth Third Bancorp
Ohio
$1K – – –
Group One Trading
34
Group One Trading
Illinois
$1K – – –
US Bancorp
35
US Bancorp
Minnesota
$1K – – –
Two Sigma Investments
36
Two Sigma Investments
New York
– -$123K -10,519 Closed
Citigroup
37
Citigroup
New York
– -$12K -1,000 Closed
SPIA
38
Steward Partners Investment Advisory
New York
– -$4.03K -344 Closed
IAIM
39
International Assets Investment Management
Florida
– -$8K -222 Closed
MAM
40
Meeder Asset Management
Ohio
– -$1K -119 Closed
Bank of America
41
Bank of America
North Carolina
– +$67 +6 +46%
1
2

LUMO Hedge Fund Activity: Q2 2021 in Review

40 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q2 2021, worth a combined $32.1M — down 17% from $38.8M a quarter earlier.

Sellers outnumbered buyers: 6 funds closed out of LUMO and 5 opened new positions — a net loss of 1 holder — while 12 trimmed existing stakes and 5 added.

The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $1.78M. The largest seller was Deerfield Management, cutting an estimated $3.78M.

  • 40 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q2 2021, down from 41 in Q1 2021.
  • Funds reported $32.1M of Lumos Pharma, Inc. Common Stock stock for Q2 2021, down 17% quarter-over-quarter.
  • 5 funds opened new Lumos Pharma, Inc. Common Stock positions in Q2 2021 and 6 closed out, a net change of -1 holder.
  • The largest Lumos Pharma, Inc. Common Stock buyer in Q2 2021 was T. Rowe Price Associates, an estimated $1.78M added.
  • The largest Lumos Pharma, Inc. Common Stock seller in Q2 2021 was Deerfield Management, an estimated $3.78M sold.

Based on aggregated 13F filings for Q2 2021.